The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning.
OBJECTIVE
The aim of this study is to determine the effects of fresh frozen plasma, as a source of cholinesterase, on butyrylcholinesterase (BuChE; plasma or pseudo cholinesterase) levels and outcomes in patients with organophosphate poisoning.


METHODS
This prospective study was performed at the Department of Intensive Care of Erciyes University Medical School. Over 2 yrs, patients admitted to the ICU for OP poisoning were entered into the study. OP poisoning was diagnosed on the basis of history and BuChE levels. All patients received atropine. Fresh frozen plasma was given to 12 patients. The study was approved by the Ethical Committee, and verbal informed consent was obtained.


RESULTS
Thirty-three patients were included in the study. BuChE levels measured at admission and the pralidoxime and atropine doses administered were not different between groups (p>0.05). Although intermediate syndrome developed in 28.6% of patients receiving pralidoxime, there were no intermediate syndrome cases in patients receiving plasma prior to developing intermediate syndrome. The mortality rates were 14.3% in the pralidoxime group and 0% in the plasma+atropine+pralidoxime group. Two patients received plasma after developing the intermediate syndrome, and one patient who received only atropine died. BuChE levels of fresh frozen plasma were 4069.5 +/- 565.1 IU/L. Every two bags of plasma provided an increase in BuChE levels of approximately 461.7 +/- 142.1 IU/L.


CONCLUSIONS
Fresh frozen plasma therapy increases BuChE levels in patients with organophosphate poisonings. The administration of plasma may also prevent the development of intermediate syndrome and related mortality. Plasma (fresh frozen or freshly prepared) therapy may be used as an alternative or adjunctive treatment method in patients with organophosphate pesticide poisoning, especially in cases not given pralidoxime. Further randomized controlled and animal studies are required to infer a definitive result.
Güven
Muhammet
M
Department of Intensive Care, Faculty of Medicine, Erciyes University Medical School, 38039, Kayseri, Turkey. mguven@erciyes.edu.tr
Sungur
Murat
M
Eser
Bülent
B
Sari
Ismail
I
Altuntaş
Fevzi
F
D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use; D002091:Butyrylcholinesterase / Q000097:blood*; D002801:Cholinesterase Reactivators / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007902:Length of Stay; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D062025:Organophosphate Poisoning; D010949:Plasma; D011220:Pralidoxime Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome
D002801:Cholinesterase Reactivators; D018727:Muscarinic Antagonists; D011220:Pralidoxime Compounds; D001285:Atropine; D002091:Butyrylcholinesterase; C028797:pralidoxime